Platelet monoamine oxidase activity in obsessive-compulsive disorder

European Psychiatry

Volumn 22, Issue 8, 2007, Pages 525-529

  Arrojo, Manuel ^a   Baca Garcia, Enrique ^b,c,d   Perez Rodriguez, Maria Mercedes ^a   Dolengevich Segal, Helen ^a   Navio Acosta, Mercedes ^a   Rodriguez Salgado, Beatriz ^a   Saiz Ruiz, Jeronimo ^a,e  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b NewYork Presbyterian Hospital   (United States)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^e UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Aggression; Obsessive compulsive disorder; Platelet MAO activity; Serotonin

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); SEROTONIN; THROMBOCYTE ENZYME;

ADULT; AGGRESSION; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME ACTIVITY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; AGGRESSION; BLOOD PLATELETS; BRAIN; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE; OBSESSIVE-COMPULSIVE DISORDER; PERSONALITY ASSESSMENT; REFERENCE VALUES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 36048966227     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2007.06.006     Document Type: Article

References (30)

1. Anthenelli R.M., Smith T.L., Craig C.E., Tabakoff B., and Schuckit M.A. Platelet monoamine oxidase activity levels in subgroups of alcoholics: diagnostic, temporal, and clinical correlates. Biol Psychiatry 38 (1995) 361-368
2. Baca-Garcia E., Salgado B.R., Segal H.D., Lorenzo C.V., Acosta M.N., Romero M.A., et al. A pilot genetic study of the continuum between compulsivity and impulsivity in females: the serotonin transporter promoter polymorphism. Prog Neuropsychopharmacol Biol Psychiatry 29 5 (2005 Jun) 713-717
3. Baca-Garcia E., Vaquero-Lorenzo C., Diaz-Hernandez M., Rodriguez-Salgado B., Dolengevich-Segal H., Arrojo-Romero M., et al. Association between obsessive-compulsive disorder and a variable number of tandem repeats polymorphism in intron 2 of the serotonin transporter gene. Prog Neuropsychopharmacol Biol Psychiatry 31 2 (2007 Mar 30) 416-420
4. Blanco C., Orensanz-Munoz L., Blanco-Jerez C., and Saiz-Ruiz J. Pathological gambling and platelet MAO activity: a psychobiological study. Am J Psychiatry 153 (1996) 119-121
5. Carrasco J.L., Diaz-Marsa M., Hollander E., Cesar J., and Saiz-Ruiz J. Decreased platelet monoamine oxidase activity in female bulimia nervosa. Eur Neuropsychopharmacol 10 (2000) 113-117
6. Cath D.C., Spinhoven P., Landman A.D., and Van Kempen G.M. Psychopathology and personality characteristics in relation to blood serotonin in Tourette's syndrome and obsessive-compulsive disorder. J Psychopharmacol 15 (2001) 111-119
7. Charney D.S., Goodman W.K., Price L.H., Woods S.W., Rasmussen S.A., and Heninger G.R. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry 45 (1988) 177-185
8. Conde V., and Franch J.I. Escalas de evaluación comportamental para la cuantificación de la sintomatología de los trastornos angustiosos y depresivos (1984), Upjohn, Madrid
9. Denys D., de Geus F., van Megen H.J., and Westenberg H.G. Use of factor analysis to detect potential phenotypes in obsessive-compulsive disorder. Psychiatry Res 128 (2004) 273-280
10. Flament M.F., Rapoport J.L., Murphy D.L., Berg C.J., and Lake C.R. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 44 (1987) 219-225
11. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46 (1989) 1006-1011
12. Hewlett W.A., Vinogradov S., Martin K., Berman S., and Csernansky J.G. Fenfluramine stimulation of prolactin in obsessive-compulsive disorder. Psychiatry Res 42 1 (1992) 81-92
13. Hollander E., DeCaria C.M., Nitescu A., Gully R., Suckow R.F., Cooper T.B., et al. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 49 (1992) 21-28
14. Hollander E., Fay M., and Cohen B. Serotoninergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioural findings. Am J Psychiatry 145 (1988) 1015-1017
15. Insel T.R., Mueller E.A., Alterman I., Linnoila M., and Murphy D.L. Obsessive-compulsive disorder and serotonin: is there a connection?. Biol Psychiatry 20 (1985) 1174-1188
16. Kaneda Y., Fujii A., and Nagamine I. Platelet serotonin concentrations in medicated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 25 (2001) 983-992
17. Karno M., Golding J.M., Sorenson S.B., and Burnam M.A. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 45 (1988) 1094-1099
18. Meltzer H.Y., and Zureick J.L. Relationship of auditory hallucinations and paranoia to platelet MAO activity in schizophrenics: sex and race interactions. Psychiatry Res 22 (1987) 99-109
19. Muck-Seler D., Pivac N., Sagud M., Jakovljevic M., and Mihaljevic-Peles A. The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 1235-1243
20. Murphy D.L., and Wyatt R.J. Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature 238 (1972) 225-226
21. Pivac N., Muck-Seler D., Sagud M., Jakovljevic M., Mustapic M., and Mihaljevic-Peles A. Long-term sertraline treatment and peripheral biochemical markers in female depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 759-765
22. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 Suppl. 20 (1998) 22-23
23. Skondras M., Markianos M., Botsis A., Bistolaki E., and Christodoulou G. Platelet monoamine oxidase activity and psychometric correlates in male violent offenders imprisoned for homicide or other violent acts. Eur Arch Psychiatry Clin Neurosci 254 6 (2004) 380-386
24. Stahl S.M. In: Longenecker G.S. (Ed). The platelets physiology and pharmacology. Platelets as pharmacological models for the receptors and biochemistry of monoaminergic neurons vol. 307 (1985), Academic, Orlando p. 340
25. Stalenheim E.G. Long-term validity of biological markers of psychopathy and criminal recidivism: follow-up 6-8 years after forensic psychiatric investigation. Psychiatry Res 121 3 (2004) 281-291
26. Sullivan J.L., Baenziger J.C., Wagner D.L., Rauscher F.P., Nurnberger Jr. J.I., and Holmes J.S. Platelet MAO in subtypes of alcoholism. Biol Psychiatry 27 (1990) 911-922
27. Thoren P., Asberg M., Cronholm B., Jornestedt L., and Traskman L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 37 (1980) 1281-1285
28. Verkes R.J., Pijl H., Meinders A.E., and Van Kempen G.M. Borderline personality, impulsiveness, and platelet monoamine measures in bulimia nervosa and recurrent suicidal behavior. Biol Psychiatry 40 (1996) 173-180
29. Weizman A., Carmi M., Hermesh H., Shahar A., Apter A., Tyano S., et al. High-affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients. Am J Psychiatry 143 (1986) 335-339
30. Zohar J., Mueller E.A., Insel T.R., Zohar-Kadouch R.C., and Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry 44 (1987) 946-951